Certara (NASDAQ:CERT) Trading 7.4% Higher – Here’s Why

Certara, Inc. (NASDAQ:CERT) shares shot up 7.4% during mid-day trading on Wednesday . The company traded as high as $13.14 and last traded at $13.55. 73,853 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 953,037 shares. The stock had previously closed at $12.61.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.92.

Certara Trading Up 5.1 %

The business’s 50 day simple moving average is $10.96 and its 200 day simple moving average is $11.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -66.33, a price-to-earnings-growth ratio of 8.77 and a beta of 1.52.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period in the prior year, the business earned $0.06 EPS. The firm’s revenue was up 10.7% compared to the same quarter last year. Research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Hedge Funds Weigh In On Certara

Several institutional investors have recently bought and sold shares of CERT. Envestnet Asset Management Inc. lifted its holdings in shares of Certara by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 573,660 shares of the company’s stock valued at $7,945,000 after buying an additional 43,403 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after purchasing an additional 273,095 shares during the period. Intech Investment Management LLC acquired a new position in shares of Certara during the 2nd quarter worth $152,000. Sei Investments Co. increased its holdings in shares of Certara by 39.5% in the 2nd quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after purchasing an additional 282,357 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its holdings in Certara by 8.0% during the second quarter. Public Sector Pension Investment Board now owns 237,075 shares of the company’s stock worth $3,283,000 after buying an additional 17,555 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.